MedTrace Logo

Stem Cells for the Treatment of Pouchitis

NCT05578508 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2026-04-16

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and feasibility of using allogeneic bone marrow derived mesenchymal stem cells (MSCs) to treat people with medically refractory Pouchitis.

Conditions

  • Pouchitis
  • Crohn's Disease
  • Ulcerative Colitis Chronic
  • Inflammatory Bowel Diseases
  • Pouch, Ileal

Interventions

DRUG

Mesenchymal Stem Cells (MSCs)

Endoscopic injection of allogeneic bone marrow derived mesenchymal stem cells (MSCs) to the ileal pouch.

Sponsors & Collaborators

  • Case Western Reserve University

    collaborator OTHER

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Amy L Lightner, MD · The Cleveland Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-30
Primary Completion
2024-02-29
Completion
2024-02-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05578508 on ClinicalTrials.gov